A 6-Week Direct-Acting Antiviral Regimen for Chronic HCV Infection

Phase IIb data show promising safety and efficacy of a 6-week, three-drug regimen in selected patients.

Currently there are 8-week regimens of direct-acting antivirals (DAAs) for the treatment of chronic hepatitis C virus (HCV) infection in patients without cirrhosis. Shorter-duration regimens have shown lower sustained virologic response (SVR) rates, typically <90%.

In phase I and IIa studies, the three-drug regimen JNJ-4178 — which includes AL-335 (NS5B polymerase inhibitor) 800 mg daily, odalasvir (NS5A inhibitor) 25 mg daily, and simeprevir (an FDA-approved protease inhibitor) 75 mg daily — appeared to be not only safe but also effective in both 6-week and 8-week courses.

In the current industry-funded, randomized, open-label, phase IIb study, investigators evaluated the safety and efficacy of 6- and 8-week courses of JNJ-4178 in both treat…

Reviewing Author

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

A 6-Week Direct-Acting Antiviral Regimen for Chronic HCV Infection

Topics

Reviewing Author